MX369394B - Compuestos de piridilo sustituidos con alquilamida utiles como muduladores de respuestas de citocinas heterodimericas interleucina 12 y 23 (il-12 e il-23) y/o interferon alfa (ifnalfa). - Google Patents

Compuestos de piridilo sustituidos con alquilamida utiles como muduladores de respuestas de citocinas heterodimericas interleucina 12 y 23 (il-12 e il-23) y/o interferon alfa (ifnalfa).

Info

Publication number
MX369394B
MX369394B MX2016005853A MX2016005853A MX369394B MX 369394 B MX369394 B MX 369394B MX 2016005853 A MX2016005853 A MX 2016005853A MX 2016005853 A MX2016005853 A MX 2016005853A MX 369394 B MX369394 B MX 369394B
Authority
MX
Mexico
Prior art keywords
ifnalpha
modulators
responses
amide
alkyl
Prior art date
Application number
MX2016005853A
Other languages
English (en)
Other versions
MX2016005853A (es
Inventor
S Tokarski John
M Moslin Ryan
S Weinstein David
T Wrobleski Stephen
E Mertzman Michael
Liu Chunjian
Zhang Yenlei
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2016005853A publication Critical patent/MX2016005853A/es
Publication of MX369394B publication Critical patent/MX369394B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos que tienen la siguiente fórmula (I) (ver Fórmula) o un estereoisómero o sal farmacéuticamente aceptable de los mismos, en donde R1, R2, R3, R4 y R5 son como se define en la presente, son útiles en la modulación de IL-12, IL-23 y/o IFNa al actuar en Tyk-2 para causar inhibición de transducción de señales.
MX2016005853A 2013-11-07 2014-01-16 Compuestos de piridilo sustituidos con alquilamida utiles como muduladores de respuestas de citocinas heterodimericas interleucina 12 y 23 (il-12 e il-23) y/o interferon alfa (ifnalfa). MX369394B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TW102140574A TWI582077B (zh) 2013-11-07 2013-11-07 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
ARP130104090A AR094537A1 (es) 2013-11-07 2013-11-07 COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
VE140013 2013-11-11
PCT/US2014/011769 WO2015069310A1 (en) 2013-11-07 2014-01-16 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses

Publications (2)

Publication Number Publication Date
MX2016005853A MX2016005853A (es) 2016-07-13
MX369394B true MX369394B (es) 2019-11-07

Family

ID=56241743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005853A MX369394B (es) 2013-11-07 2014-01-16 Compuestos de piridilo sustituidos con alquilamida utiles como muduladores de respuestas de citocinas heterodimericas interleucina 12 y 23 (il-12 e il-23) y/o interferon alfa (ifnalfa).

Country Status (31)

Country Link
US (2) US9663467B2 (es)
EP (2) EP3590926A1 (es)
JP (1) JP6312823B2 (es)
KR (1) KR102186633B1 (es)
CN (1) CN106660960B (es)
AR (1) AR094537A1 (es)
AU (1) AU2014347275B2 (es)
CA (1) CA2930060C (es)
CL (1) CL2016001101A1 (es)
CY (1) CY1122065T1 (es)
DK (1) DK3066078T3 (es)
EA (1) EA033272B1 (es)
ES (1) ES2738826T3 (es)
HK (1) HK1226400A1 (es)
HR (1) HRP20191368T1 (es)
HU (1) HUE046052T2 (es)
IL (1) IL245448B (es)
LT (1) LT3066078T (es)
MA (1) MA39001A1 (es)
MX (1) MX369394B (es)
MY (1) MY174453A (es)
NZ (1) NZ720710A (es)
PE (1) PE20160961A1 (es)
PH (1) PH12016500779A1 (es)
PL (1) PL3066078T3 (es)
PT (1) PT3066078T (es)
RS (1) RS59125B1 (es)
SI (1) SI3066078T1 (es)
TN (1) TN2016000153A1 (es)
TW (1) TWI582077B (es)
WO (1) WO2015069310A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015009798A2 (pt) 2012-11-08 2017-07-11 Bristol Myers Squibb Co compostos de pirimidina substituídos por alquil amida úteis na modulação de il-12, il-23 e/ou ifnalfa
ES2702148T3 (es) 2012-11-08 2019-02-27 Bristol Myers Squibb Co Compuestos heterocíclicos sustituidos con amida útiles como moduladores de il-12, il-23 y/o ifn-alfa
CA2916615A1 (en) 2013-07-01 2015-01-08 Bristol-Myers Squibb Company Ido inhibitors
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
CN105992768B (zh) 2013-12-10 2018-04-20 百时美施贵宝公司 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
TW201718571A (zh) 2015-06-24 2017-06-01 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
JP6720225B2 (ja) 2015-06-24 2020-07-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリール置換のアミノピリジン化合物
CA3039202A1 (en) 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
KR102477063B1 (ko) 2016-10-28 2022-12-12 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물
JP7012082B2 (ja) * 2016-11-17 2022-01-27 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎ－アルファのイミダゾピリダジン調節剤
JP7046092B2 (ja) * 2016-12-13 2022-04-01 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤としてのホスフィンオキシドアルキルアミド置換ヘテロアリール化合物
AU2018244916B2 (en) * 2017-03-30 2021-11-18 Bristol-Myers Squibb Company Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide
PL3621960T3 (pl) 2017-05-11 2021-11-08 Bristol-Myers Squibb Company Tienopirydyny i benzotiofeny użyteczne jako inhibitory irak4
SG11202004592TA (en) * 2017-11-21 2020-06-29 Bristol Myers Squibb Co Sulfone pyridine alkyl amide-substituted heteroaryl compounds
WO2019178079A1 (en) 2018-03-12 2019-09-19 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
US11572360B2 (en) * 2018-08-16 2023-02-07 Innate Tumor Immunity, Inc. Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
CA3117200A1 (en) * 2018-10-22 2020-04-30 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
CA3118094A1 (en) * 2018-10-30 2020-05-07 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha
CN117263918A (zh) * 2019-01-28 2023-12-22 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
CN113365982A (zh) * 2019-01-30 2021-09-07 百时美施贵宝公司 酰胺二取代的吡啶或哒嗪化合物
SG11202112043PA (en) 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors
US20220204495A1 (en) * 2019-05-03 2022-06-30 Valo Health, Inc. Inhibiting trabid
EP3999499A1 (en) * 2019-07-16 2022-05-25 Bristol-Myers Squibb Company Prodrugs in the modulation of interleukin
JP2023524361A (ja) * 2020-03-11 2023-06-12 ベイジン・イノケア・ファーマ・テク・カンパニー・リミテッド Ｔｙｋ２活性を阻害する複素環式化合物
WO2021204626A1 (en) * 2020-04-06 2021-10-14 Almirall, S.A. Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors
US20230295119A1 (en) * 2020-04-14 2023-09-21 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
KR20230004771A (ko) * 2020-04-28 2023-01-06 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물
CN113563309A (zh) * 2020-04-28 2021-10-29 浙江海正药业股份有限公司 吡啶类衍生物及其制备方法和用途
WO2021237121A1 (en) * 2020-05-21 2021-11-25 Gossamer Bio Services, Inc. Substituted pyridines
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
TW202227430A (zh) * 2020-11-17 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類衍生物、其製備方法及其在醫藥上的應用
CN112625030A (zh) * 2020-12-25 2021-04-09 杭州澳赛诺生物科技有限公司 一种一锅法合成n-保护3-溴代吡唑的合成方法
TW202233600A (zh) * 2021-02-06 2022-09-01 大陸商正大天晴藥業集團股份有限公司 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途
EP4308556A1 (en) * 2021-03-16 2024-01-24 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
JP2024517453A (ja) * 2021-05-04 2024-04-22 シャンハイ ゼイ バイオテクノロジー カンパニー リミテッド 含窒素複素環ピリジン化合物
WO2022253335A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 含磺酰基的芳基类化合物及其应用
WO2023049241A1 (en) * 2021-09-23 2023-03-30 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
CA3236262A1 (en) 2021-10-25 2023-05-04 Isaac Marx Tyk2 degraders and uses thereof
WO2023108536A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
AU2022412835A1 (en) * 2021-12-16 2024-06-20 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
WO2023213308A1 (zh) * 2022-05-05 2023-11-09 苏州隆博泰药业有限公司 酰胺取代的杂环化合物及其医药用途
WO2024020221A1 (en) 2022-07-21 2024-01-25 Arvinas Operations, Inc. Modulators of tyk2 proteolysis and associated methods of use
WO2024042363A1 (en) * 2022-08-24 2024-02-29 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
WO2024042361A1 (en) * 2022-08-24 2024-02-29 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
AR076550A1 (es) * 2009-05-06 2011-06-22 Portola Pharm Inc Inhibidores de la janus tirosina kinasa (jak)
AR077033A1 (es) * 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
WO2013054351A1 (en) * 2011-08-08 2013-04-18 Cadila Healthcare Limited Heterocyclic compounds
US9060515B2 (en) * 2011-12-21 2015-06-23 Biota Europe Ltd. Heterocyclic urea compounds
KR20140114344A (ko) * 2011-12-23 2014-09-26 셀좀 리미티드 키나제 억제제로서의 피리미딘-2,4-디아민 유도체
BR112015009798A2 (pt) 2012-11-08 2017-07-11 Bristol Myers Squibb Co compostos de pirimidina substituídos por alquil amida úteis na modulação de il-12, il-23 e/ou ifnalfa
ES2702148T3 (es) 2012-11-08 2019-02-27 Bristol Myers Squibb Co Compuestos heterocíclicos sustituidos con amida útiles como moduladores de il-12, il-23 y/o ifn-alfa
BR112015010244A8 (pt) 2012-11-08 2019-10-01 Bristol Myers Squibb Co compostos de piridila substituída por alquil-amida úteis como moduladores de il-12, il-23 e/ou respostas de ifnalfa, sua composição farmacêutica e seu uso
CN105992768B (zh) 2013-12-10 2018-04-20 百时美施贵宝公司 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物

Also Published As

Publication number Publication date
ES2738826T3 (es) 2020-01-27
KR102186633B1 (ko) 2020-12-03
US9663467B2 (en) 2017-05-30
MX2016005853A (es) 2016-07-13
MA39001A1 (fr) 2017-10-31
JP6312823B2 (ja) 2018-04-18
PE20160961A1 (es) 2016-10-08
HUE046052T2 (hu) 2020-02-28
PL3066078T3 (pl) 2019-10-31
IL245448A0 (en) 2016-06-30
JP2017512749A (ja) 2017-05-25
EP3590926A1 (en) 2020-01-08
TWI582077B (zh) 2017-05-11
HK1226400A1 (zh) 2017-09-29
CY1122065T1 (el) 2020-11-25
AR094537A1 (es) 2015-08-12
RS59125B1 (sr) 2019-09-30
BR112016010172A2 (pt) 2017-08-08
EP3066078A1 (en) 2016-09-14
LT3066078T (lt) 2019-07-25
HRP20191368T1 (hr) 2019-11-29
MY174453A (en) 2020-04-20
CL2016001101A1 (es) 2016-12-16
PH12016500779A1 (en) 2016-05-30
CN106660960B (zh) 2019-11-08
IL245448B (en) 2019-08-29
EA033272B1 (ru) 2019-09-30
EA201690865A1 (ru) 2017-01-30
DK3066078T3 (da) 2019-08-26
PT3066078T (pt) 2019-08-01
KR20160071475A (ko) 2016-06-21
US9987266B2 (en) 2018-06-05
CN106660960A (zh) 2017-05-10
EP3066078B1 (en) 2019-05-22
US20160280649A1 (en) 2016-09-29
AU2014347275A1 (en) 2016-06-23
CA2930060A1 (en) 2015-05-14
TN2016000153A1 (en) 2017-10-06
AU2014347275B2 (en) 2017-12-07
WO2015069310A1 (en) 2015-05-14
SI3066078T1 (sl) 2019-08-30
NZ720710A (en) 2019-12-20
US20170209426A1 (en) 2017-07-27
CA2930060C (en) 2020-03-24
TW201420572A (zh) 2014-06-01

Similar Documents

Publication Publication Date Title
PH12016500779A1 (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses
MY175448A (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifna responses
TN2015000175A1 (en) Heteroaryl substituted pyridyl compounds useful as kinase modulators
EA201590913A1 (ru) АЛКИЛАМИДЗАМЕЩЕННЫЕ ПИРИДИЛЬНЫЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОТВЕТОВ, ОПОСРЕДУЕМЫХ IL-12, IL-23 И/ИЛИ IFNα
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
JO3515B1 (ar) مثبطات fgfr4 بيريميدين
PH12015501843A1 (en) Novel pyrazol derivatives
PH12015501933A1 (en) Novel pyridine derivatives
EA201590911A1 (ru) АЛКИЛАМИДЗАМЕЩЁННЫЕ ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ МОДУЛЯЦИИ IL-12, IL-23 И/ИЛИ IFNα
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
PH12016501865A1 (en) Pyridine-2-amides useful as cb2 agonists
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
TR201902875T4 (tr) Plk-4 inhibitörünün tuz ve kristal formları.
BR112016027455A2 (pt) moduladores ppar
MX2015016766A (es) Nuevos derivados de tetrazolona.
PH12018501585B1 (en) Novel pyrrolidine derivatives
EP3414347A4 (en) ADDITIVE FOR IMPROVING SEQUENCING THROUGH SYNTHETIC PERFORMANCE
MX2015009377A (es) Compuestos radiomarcados.
MX2018011117A (es) Forma cristalina.
IN2013MU02800A (es)
PL405775A1 (pl) Nowy związek, zwłaszcza do stosowania jako pigment

Legal Events

Date Code Title Description
FG Grant or registration